Loading
Treatment Resistant Major Depression Disorder / Precuneus-targeted continuous theta-burst stimulation / Treatment Resistant Depression (TRD) · Interventional Study
ClinicalTrials.gov · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned randomized controlled trial comparing two one-day accelerated TMS protocols (precuneus-targeted cTBS and left DLPFC iTBS) against sham stimulation in adults with treatment-resistant depression. No results are available in this registry record; the study has not yet begun enrollment and its efficacy and safety remain unknown.
Interventional, Randomized, Parallel, Single masking, Treatment purpose. Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD), Treatment Resistant Major Depression Disorder; age from 18 Years. Intervention: Precuneus cTBS; Left dlPFC iTBS. Compared with: Sham TMS — Sham Comparator. n = 69. 1 site: United States.
This is a planned randomized controlled trial comparing two one-day accelerated TMS protocols (precuneus-targeted cTBS and left DLPFC iTBS) against sham stimulation in adults with treatment-resistant depression. No results are available in this registry record; the study has not yet begun enrollment and its efficacy and safety remain unknown.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If positive results emerge, this trial could inform whether one-day accelerated TMS targeting novel brain regions (precuneus) offers efficacy in TRD comparable to or exceeding established DLPFC protocols. Currently, no clinical recommendation can be made pending completion and publication of results.
This is a clinical trial registry record with no results posted; the study is not yet recruiting and describes planned methodology only for an accelerated TMS intervention in treatment-resistant depression.
As stated by the source record.
Quoted from the source exactly as published.
If positive results emerge, this trial could inform whether one-day accelerated TMS targeting novel brain regions (precuneus) offers efficacy in TRD comparable to or exceeding established DLPFC protocols. Currently, no clinical recommendation can be made pending completion and publication of results.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07758010). This is a study registration, not published results. Lead sponsor: Mclean Hospital. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 69 participants (ESTIMATED). Conditions: Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD), Treatment Resistant Major Depression Disorder. Interventions: DEVICE: Precuneus-targeted continuous theta-burst stimulation; DEVICE: Left dorsolateral prefrontal cortex intermittent theta-burst stimulation; DEVICE: Sham transcranial magnetic stimulation. Primary outcome measures: Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 4 , Baseline and 1, 2, 3, and 4 weeks after the intervention. Brief summary: The goal of this clinical trial is to learn whether two forms of one-day accelerated transcranial magnetic stimulation (TMS) can reduce depressive symptoms in adults with treatment-resistant depression. Treatment-resistant depression is depression that has not improved enough after at least two adequate antidepressant medication treatments. TMS is a non-invasive treatment that uses magnetic pulses to stimulate specific areas of the brain. The main questions this study aims to answer are: * Does continuous theta-burst stimulation (cTBS) targeting the precuneus reduce depressive symptoms 4 weeks after treatment compared with sham stimulation? * Does intermittent theta-burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex reduce depressive symptoms 4 weeks after treatment compared with sham stimulation? Researchers will compare precuneus cTBS, left dorsolateral prefrontal cortex iTBS, and sham stimulation to determine whether either active treatment reduces depressive symptoms more than sham stimulation. Participants will be randomly assigned to one of the three groups and will not be told which treatment they initially receive. Participants will: * Complete screening procedures and baseline assessments of depression, rumination, and cognitive function * Receive 20 sessions of active or sham TMS during one in-person study day * Complete follow-up assessments 1, 2, 3, and 4 weeks after the intervention * Report any side effects or medical problems experienced during the study Participants initially assigned to sham stimulation may choose to receive active TMS after completing the 4-week follow-up period. Those who choose this option will receive either precuneus cTBS or left dorsolateral prefrontal cortex iTBS and will complete additional follow-up assessments.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.